Molecular Test Detects Bile Duct Cancer at Twice the Rate of Standard Methods
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Latest Articles
Editor's Top Picks
Ordering Both ESR and CRP Tests Could Save Hospitals Nearly $10 Million Per Year, Study Finds
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
New 4-in-1 Blood Donor Screening Assay Targets HIV, Hepatitis B, C, and E in a Single Workflow
The cobas MPX-E assay is now available in CE-mark accepting countries, offering labs a scalable, automated solution for multiplex nucleic acid testing.
Equipment & Supply Spotlight
12 Life Science Startups Named to SLAS Europe 2026 Innovation Showcase Program
Emerging companies from six countries will exhibit enabling technologies at the Society of Laboratory Automation and Screening's annual European conference in Vienna this May.
News, Know-How & Standards
Disease Detection & Understanding
Concussion Blood Test Advances Toward FDA Submission With Point-of-Care Collaboration
BRAINBox Solutions reports near-completion of its HeadSMART II trial for a concussion blood test, supporting an upcoming FDA submission, and advances in a point-of-care biomarker collaboration with Prolight Diagnostics.
